Atara's Outlook As Ebvallo Hits Second FDA CRL

Benzinga_recent_news01-15

Atara Biotherapeutics (NASDAQ:ATRA) has developed Ebvallo (tabelecleucel), a novel second-line immunotherapy for Epstein–Barr virus–positive post-transplant lymphoproliferative disease (EBV-PTLD). The...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2603649942?lang=en_US&edition=fundamental","thumbnail":"https://static.tigerbbs.com//next-assets/images/benzinga-post-card-placeholder.svg?optimize=medium&dpr=2&auto=webp&width=240?op=imageView2&mode=2&width=256&height=256&quality=70&format=png","is_english":true,"pubTime":"2026-01-15 02:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2603649942","market":"sh","top_or_hot":-1,"title":"Atara's Outlook As Ebvallo Hits Second FDA CRL","media":"Benzinga_recent_news","content":"<div>\n<p>Atara Biotherapeutics (NASDAQ:ATRA) has developed Ebvallo (tabelecleucel), a novel second-line immunotherapy for Epstein–Barr virus–positive post-transplant lymphoproliferative disease (EBV-PTLD).\nThe...</p>\n\n<a href=\"https://www.benzinga.com/Opinion/26/01/49916695/atara-outlook-as-ebvallo-hits-second-fda-crl\">Source Link</a>\n\n</div>\n","source":"benzinga_recent_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Atara's Outlook As Ebvallo Hits Second FDA CRL</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAtara's Outlook As Ebvallo Hits Second FDA CRL\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-01-15 02:28 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/Opinion/26/01/49916695/atara-outlook-as-ebvallo-hits-second-fda-crl><strong>Benzinga_recent_news</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Atara Biotherapeutics (NASDAQ:ATRA) has developed Ebvallo (tabelecleucel), a novel second-line immunotherapy for Epstein–Barr virus–positive post-transplant lymphoproliferative disease (EBV-PTLD).\nThe...</p>\n\n<a href=\"https://www.benzinga.com/Opinion/26/01/49916695/atara-outlook-as-ebvallo-hits-second-fda-crl\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4121","symbol_name":"生命科学工具和服务","start_time":0,"source_url":"https://www.benzinga.com/Opinion/26/01/49916695/atara-outlook-as-ebvallo-hits-second-fda-crl","article_id":"2603649942","we_media_id":null,"thumbnails":["https://static.tigerbbs.com//next-assets/images/benzinga-post-card-placeholder.svg?optimize=medium&dpr=2&auto=webp&width=240?op=imageView2&mode=2&width=256&height=256&quality=70&format=png"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/Opinion/26/01/49916695/atara-outlook-as-ebvallo-hits-second-fda-crl","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2603649942","pubTimestamp":1768415280,"columns":[],"sourceInfo":{"source_id":"benzinga_recent_news","name":"Benzinga"},"weMediaInfo":null,"summary":"The BLA is primarily supported by data from the Phase 3, single-arm, open-label ALLELE trial . In the ALLELE trial, Ebvallo met its prespecified primary efficacy endpoint and demonstrated a generally tolerable safety profile.It is noteworthy that Ebvallo had already received European Commission marketing authorization in the EU on 16 December 2022.In the U.S., Ebvallo previously received a CRL on January 15, 2025, which identified a single manufacturing compliance deficiency and did not raise concerns regarding safety, efficacy, or trial design.On January 9, 2026, Atara received a second FDA Complete Response Letter  for the Biologics License Application  for Ebvallo.Atara is currently at an extremely constrained net liquidity level. However, Atara has already monetized a portion of its Ebvallo EU royalty and certain milestone economics through the HCRx royalty-interest transaction. As Ebvallo has now been rejected by the FDA, the company may have very few remaining unencumbered assets","collect":0,"end_time":0,"defaultTopTitle":"benzinga.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4121":"生命科学工具和服务","LU0757428866.USD":"THREADNEEDLE (LUX) GLOBAL SMALLER COMPANIES \"AE\" (USD) ACC","LU0390134368.USD":"FRANKLIN GLOBAL GROWTH \"A\" (USD) ACC","LU0029874061.USD":"TEMPLETON GLOBAL SMALLER COMPANIES \"A\" YDIS INC","IE00BFMHRM44.USD":"NEUBERGER BERMAN GLOBAL EQUITY MEGATRENDS \"A\" (USD) ACC","BK4139":"生物科技","BK4530":"医药外包概念","CRL":"查尔斯河","LU1815336091.USD":"THREADNEEDLE (LUX) GLOBAL SMALLER COMPANIES \"AUP\" (USD) INC","ATRA":"Atara Biotherapeutics","BK4588":"碎股","BK4585":"ETF&股票定投概念","LU0128526141.USD":"TEMPLETON GLOBAL SMALLER COMPANIES \"A\" ACC"},"translate_title":"Ebvallo获得第二个FDA CRL后Atara的前景","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CRL":1.5,"ATRA":1},"content_text":"Atara Biotherapeutics (NASDAQ:ATRA) has developed Ebvallo (tabelecleucel), a novel second-line immunotherapy for Epstein–Barr virus–positive post-transplant lymphoproliferative disease (EBV-PTLD).\nThe BLA is primarily supported by data from the Phase 3, single-arm, open-label ALLELE trial (NCT03394365). In the ALLELE trial, Ebvallo met its prespecified primary efficacy endpoint and demonstrated a generally tolerable safety profile.\nThe Regulatory Timeline\nIt is noteworthy that Ebvallo had already received European Commission marketing authorization in the EU on 16 December 2022.\nIn the U.S., Ebvallo previously received a CRL on January 15, 2025, which identified a single manufacturing compliance deficiency and did not raise concerns regarding safety, efficacy, or trial design.\nOn January 9, 2026, Atara received a second FDA Complete Response Letter (CRL) for the Biologics License Application (BLA) for Ebvallo.\nSecond CRL: Core Issue\nThe BLA is primarily supported by data from the Phase 3, single-arm, open-label ALLELE trial (NCT03394365). In the ALLELE trial, Ebvallo met its prespecified primary efficacy endpoint and demonstrated a generally tolerable safety profile.\nIn the new CRL, the previously cited manufacturing deficiencies were resolved. However, the FDA stated that it cannot approve the BLA in its current form, citing concerns that the ALLELE trial is no longer considered adequate to demonstrate effectiveness for accelerated approval due to interpretability issues related to trial design, conduct, and analysis.\nNotably, this CRL is not driven by manufacturing or safety issues, nor by a failed efficacy signal in the current data. Instead, it reflects a change in the FDA's assessment of whether the existing dataset is considered sufficient to support accelerated approval.\nWhat Comes Next\nAtara is currently at an extremely constrained net liquidity level. However, Atara has already monetized a portion of its Ebvallo EU royalty and certain milestone economics through the HCRx royalty-interest transaction. As Ebvallo has now been rejected by the FDA, the company may have very few remaining unencumbered assets or cash-flow streams left to sell or finance in the near term.\nGiven the information in the CRL, the most likely path forward is that Atara and Pierre Fabre Pharmaceuticals, which assumed sponsorship of the BLA from Atara in November 2025, will need to conduct an additional clinical trial to address the FDA's concerns.\nSpeaking of cost, the new trial's direct cost burden most likely sits with Pierre Fabre, not Atara. However, SEC filings note that Atara agreed to provide and/or extend certain services to Pierre Fabre at Atara's cost, which still makes Atara economically impacted. As the FDA wants a more credible design to remove \"confounding,\" this may result in requiring a randomized or more stringent confirmatory design, which can push timelines toward 2–3 years.\nBenzinga Disclaimer: This article is from an unpaid external contributor. It does not represent Benzinga’s reporting and has not been edited for content or accuracy.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"policyRegulatory","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.1","shortVersion":"4.36.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2603649942","isCrawlerRequest":true}